Arrowhead Pharmaceuticals, Inc. (ARWR)财务
NASDAQ · Healthcare · Biotechnology · 员工711人 · CEO Christopher R. Anzalone
- 股价
- $59.90 -0.98%
- 市值
- $84.6亿
- 企业价值
- $92.7亿
- 最近财报
- Q3 '26 2026-08-04提交
- 下次财报
- 2026-11-24 EPS预期 -$1.52
营收(TTM)$6.69亿+16.8% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)-33.8%-15.0 百分点 对比去年同期营业利润 -$2.26亿
净利润(TTM)-$3.2亿-115.6% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$7510万-326.3% 对比去年同期资本支出 $1610万
稀释EPS(TTM)-$2.24-72.3% 对比去年同期最近4个季度之和
净现金$7.38亿+294.4% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $84.6亿 EV $92.7亿
- 营收
- $6.69亿 过去12个月
- 营收增速
- -44% FY2026年一致预期
- 净利润率
- -47.8% 净利润 / 营收,TTM
- P/E
- -26.7× 预期 -17.0×(FY2026)
- P/S
- 12.6× 股价 / 营收,TTM
- EV / EBITDA
- -69.4× TTM
- 自由现金流
- -$7510万 过去12个月
- 净利润
- -$3.2亿 过去12个月
- 营收预期
- $4.64亿 FY2026年一致预期
- 盈利
- 2026-11-24 营收预期 $6120万
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-04):营收超预期70.4%,EPS 低于预期6.3%营收$7530万,预期$4420万(+70.4%);EPS -$1.36,预期-$1.28(-6.3%)。
- 营收增长放缓:同比171.0%Q3 '26营收$7530万,此前四个季度的平均值为5,187.5%。
- 营业利润率-33.8%(TTM),较去年同期-15.0 百分点营收增长16.8%,营业利润增长-109.7%。
- 资本支出占营收的2.4%(去年为6.9%)最近4个季度投入$1610万(同比-59.3%)。自由现金流-$7510万。
- 稀释股数一年内增加3.1%Q3 '26稀释股数1.43亿,一年前为1.39亿。
- 净现金 $7.38亿现金 + 短期投资 $16亿,含租赁债务 $8.64亿;一年前净现金 $1.87亿。
上一季度:Q3 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $7530万 | $2780万 | +171.0% |
| 毛利率 | 100.0% | 100.0% | 0.0 百分点 |
| 营业利润 | -$1.7亿 | -$1.66亿 | -2.7% |
| 营业利润率 | -226.0% | -596.2% | +370.2 百分点 |
| 净利润 | -$1.94亿 | -$1.75亿 | -10.9% |
| 稀释EPS | -$1.36 | -$1.26 | -7.9% |
| 经营现金流 | -$1.77亿 | -$1.55亿 | -14.7% |
| 资本支出 | $385万 | $236万 | +63.0% |
| 自由现金流 | -$1.81亿 | -$1.57亿 | -15.4% |
| R&D | $1.98亿 | $1.62亿 | +22.1% |
| 股权激励费用 | $1470万 | $1300万 | +12.9% |
实际 vs 一致预期
2026-08-04| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $7530万 | $4420万 | +70.4% |
| EPS(一致预期口径) | -$1.36 | -$1.28 | -6.3% |
来自2026-08-04发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$5910万
- 资本支出
- -$1610万
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $11.9亿
- 股权激励费用
- $7000万
- 自由现金流
- -$7510万
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -26.7× | – | – |
| EV / EBITDA | -69.4× | 28.8× 5年中的1年 | 28.8× – 28.8× |
| EV / 营收 | 13.8× | 188.6× | 5.7× – 864.4× |
| 股价 / FCF | -112.6× | 36.6× 5年中的2年 | 29.4× – 43.8× |
| 股价 / 净资产 | 18.4× | 11.5× | 8.7× – 15.8× |
| FCF收益率 | -0.9% | -7.5% | -26.0% – 3.4% |
| 投入资本回报率 | -12.1% | -28.3% | -57.4% – 4.6% |
| 净资产收益率 | -60.5% | -95.6% | -323.3% – -0.3% |
分析师
一致目标价 $101.56 (+69.5%)
区间 $46.00 – $126.00 · 评级 Buy
强烈买入0
买入16
持有6
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $4.64亿 | -44.0% | -$3.52 | -28,781.2% | -17.0× | 12 |
| FY2027 | $3.3亿 | -28.9% | -$4.86 | -37.8% | -12.3× | 13 |
| FY2028 | $6.66亿 | +101.8% | -$2.81 | +42.1% | -21.3× | 8 |
| FY2029 | $11.5亿 | +72.3% | -$0.74 | +73.8% | -81.4× | 5 |
| FY2030 | $20.4亿 | +78.1% | $4.41 | +698.7% | 13.6× | 3 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Arrowhead Pharmaceuticals, Inc.在近期10-Q / 10-K文件中标记的全部228项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $2780万 | $3310万 | -16.0% | $1770万 | $1140万 | +55.2% |
| Accounts Receivable, after Allowance for Credit Loss | $580万 | $970万 | -40.2% | $682万 | $0 | – |
| Accounts Receivable, after Allowance for Credit Loss, Current | $856万 | $970万 | -11.8% | $682万 | $0 | – |
| Accrued Income Taxes, Current | $0 | – | – | $2080万 | $0 | – |
| Accrued Liabilities, Current | $8620万 | $6480万 | +32.9% | $9040万 | $6300万 | +43.5% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $9720万 | $7420万 | +31.0% | $8020万 | $5800万 | +38.2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$123万 | $536万 | -123.0% | $644万 | $475万 | +35.6% |
| Additional Paid in Capital, Common Stock | $24.4亿 | $21.2亿 | +15.2% | $21.4亿 | $18.1亿 | +18.5% |
| Adjustments to Additional Paid in Capital, Warrant Issued | $1亿2026-03-31 | – | – | $2500万 | – | – |
| Amortization of Debt Issuance Costs | $76.6万 | $0 | – | – | – | – |
| Amortization of Intangible Assets | $40万 | $40万 | 0.0% | $170万 | $170万 | 0.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1470万 | 595万 | +146.6% | 502万 | 474万 | +6.0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $1490万 | $1300万 | +14.0% | $6340万 | $7400万 | -14.3% |
| Assets | $21.1亿 | $13.8亿 | +53.0% | $13.9亿 | $11.4亿 | +21.5% |
| Assets, Current | $16.7亿 | $9.47亿 | +76.5% | $9.51亿 | $6.95亿 | +36.7% |
| Assets, Fair Value Disclosure | $15.8亿 | – | – | – | – | – |
| Capital Expenditures Incurred but Not yet Paid | $75万 | -$1.2万 | +6,350.0% | $27.7万 | $421万 | -93.4% |
| Cash and Cash Equivalents, Fair Value Disclosure | $3220万 | – | – | – | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $5480万 | $1.3亿 | -57.8% | $2.27亿 | $1.03亿 | +120.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | -$1.34亿 | -$5600万 | -139.7% | $1.24亿 | -$1240万 | +1,101.9% |
| Class of Warrant or Right, Exercise Price of Warrants or Rights | – | – | – | $0.002024-11-25 | – | – |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | – | – | – | 91.7万2024-11-25 | – | – |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 2.9亿 | 2.9亿 | 0.0% | 2.9亿 | 2.9亿 | 0.0% |
| Common Stock, Shares, Issued | 1.44亿 | 1.38亿 | +4.1% | 1.36亿 | 1.24亿 | +9.1% |
| Common Stock, Shares, Outstanding | 1.41亿 | 1.38亿 | +2.2% | 1.36亿 | 1.24亿 | +9.1% |
| Common Stock, Value, Issued | $23.7万 | $23万 | +3.0% | $23.1万 | $21.7万 | +6.5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $1560万 | -$341万 | +556.6% | $3170万 | -$1020万 | +411.2% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$1.96亿 | -$1.74亿 | -12.6% | -$1.41亿2021-09-30 | -$8410万 | -67.5% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | -$1.81亿 | -$1.78亿 | -1.7% | $3180万 | -$6.02亿 | +105.3% |
| Contract with Customer, Asset, after Allowance for Credit Loss, Current | $1020万 | – | – | – | – | – |
| Contract with Customer, Liability | $240万2025-09-30 | $0 | – | $240万 | $0 | – |
| Contract with Customer, Liability, Current | $9460万 | $2300万 | +311.7% | $240万 | $0 | – |
| Contract with Customer, Liability, Noncurrent | $3170万 | $0 | – | $02023-09-30 | $5600万 | -100.0% |
| Contract with Customer, Liability, Revenue Recognized | -$4660万 | -$2760万 | -68.8% | – | – | – |
| Convertible Debt | $6.83亿 | – | – | – | – | – |
| Convertible Debt, Noncurrent | $6.83亿 | – | – | – | – | – |
| Current Federal Tax Expense (Benefit) | – | – | – | $2140万 | $14.8万 | +14,386.5% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $3.5万 | -$329万 | +101.1% |
| Current Income Tax Expense (Benefit) | – | – | – | $2140万 | -$277万 | +874.1% |
| Current State and Local Tax Expense (Benefit) | – | – | – | -$5.6万 | $37.5万 | -114.9% |
| Debt Securities, Available-for-sale | $15.5亿 | $7.71亿 | +100.8% | $6.93亿 | $5.78亿 | +19.8% |
| Debt Securities, Available-for-sale, Amortized Cost, Current | $15.5亿 | $7.69亿 | +102.1% | $6.9亿 | $5.77亿 | +19.5% |
| Debt Securities, Available-for-sale, Current | $15.5亿 | $7.71亿 | +100.8% | $6.93亿 | $5.78亿 | +19.8% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year | $6.05亿 | $2.25亿 | +169.6% | – | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $2.24亿2025-09-30 | $5.78亿 | -61.2% | $2.24亿 | $5.78亿 | -61.2% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Assets, Deferred Income | $1.71亿2025-09-30 | $8160万 | +110.0% | $1.71亿 | $8160万 | +110.0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $103万2025-09-30 | $138万 | -25.3% | $103万 | $138万 | -25.3% |
| Deferred Tax Assets, Gross | $5.63亿2025-09-30 | $4.73亿 | +19.0% | $5.63亿 | $4.73亿 | +19.0% |
| Deferred Tax Assets, Net | $02025-09-30 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Operating Loss Carryforwards | $7090万2025-09-30 | $1.03亿 | -31.0% | $7090万 | $1.03亿 | -31.0% |
| Deferred Tax Assets, Other | $94.8万2025-09-30 | $284万 | -66.7% | $94.8万 | $284万 | -66.7% |
| Deferred Tax Assets, Tax Credit Carryforwards | $4890万2025-09-30 | $8540万 | -42.8% | $4890万 | $8540万 | -42.8% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $425万2025-09-30 | $408万 | +4.3% | $425万 | $408万 | +4.3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $918万2025-09-30 | $1100万 | -16.4% | $918万 | $1100万 | -16.4% |
| Deferred Tax Assets, Valuation Allowance | $4.98亿2025-09-30 | $4.49亿 | +10.8% | $4.98亿 | $4.49亿 | +10.8% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02